兰州大学机构库 >学院待认领
胃癌两种新辅助化疗方案比较及Her-2、Ki-67表达相关性研究
Alternative TitleComparison of two neoadjuvant chemotherapies regimens and study of the correlation the expression of Her-2 and Ki-67 with gastric cancer
赵若羽
Thesis Advisor沈世林
2015-05-26
Degree Grantor兰州大学
Place of Conferral兰州
Degree Name硕士
Keyword胃癌 xelox sox 疗效 Her-2 Ki-67
Abstract目的:1.比较xelox方案与Sox方案用于胃癌新辅助化疗的疗效;2.河西地区胃癌患者Her-2、Ki-67蛋白表达相关性。 方法:1. xelox方案新辅助化疗40例,sox方案46例。比较两组患者的近期疗效和术后肿瘤分期。2. IHC检测得到的Her-2、Ki-67蛋白结果分为阳性组和阴性组,进行两组间统计分析。 结果:1. PR的患者sox组多于xelox组, PD的患者xelox组多于sox组。术后分期Ⅰ、Ⅱ期sox组多于xelox组,而Ⅲ、Ⅳ期xelox组多于sox组。2. Her-2阳性表达率52%。高分化腺癌患者Her-2阳性组多于阴性组;低分化腺癌患者Her-2阴性组多于阳性组。Ⅰ期患者Her-2阴性组多于阳性组;Ⅲ期患者Her-2阳性组多于阴性组。贲门处患者Her-2阳性组多于阴性组;胃小弯处患者Her-2阴性组多于阳性组。3. Ki-67阳性表达率45%。低分化腺癌患者Ki-67阳性组多于阴性组。Ⅰ期患者Ki-67阴性组多于阳性组;Ⅲ期患者Ki-67阳性组多于Ki-67阴性组。贲门处患者Ki-67阳性组多于阴性组。 结论 :1. 与xelox方案相比,sox方案用于胃癌的新辅助化疗可更加显著提高近期疗效。2. Her-2在高分化腺癌中高表达,低分化腺癌中低表达。3. Her-2在Ⅰ期时低表达,Ⅲ期时高表达。4. Her-2于贲门处高表达,胃小弯处低表达。5. Ki-67在低分化腺癌中高表达。6. Ki-67在Ⅰ期时低表达,Ⅲ期时高表达。7. Ki-67于贲门处高表达。 关键词:胃癌,xelox,sox,疗效,Her-2,Ki-67
Other AbstractObjectives(1)To compare the efficacy of xelox and Sox neoadjuvant chemotherapies in the treatment of gastric cancer. (2) To study the correlations the expression status of Her-2 and Ki-67 proteins in patients with gastric carncer in Hexi Area. Methods:(1)the xelox group (40cases) and the Sox group (46cases). the xelox and Sox groups are compared in terms of recent efficacy, tumor stages . (2) surgical specimens are examined Her-2 and Ki-67 proteins by IHC method. These cases are then divided into the positive group and the negative group based on their IHC results and the statistic is then analyzed in each clinical observation category. Results:(1) To the PR, sox neoadjuvant chemotherapy is more than xelox neoadjuvant chemotherapy. To the PD, xelox neoadjuvant chemotherapy is more than sox neoadjuvant chemotherapy. The cases of sox neoadjuvant chemotherapy is more than xelox neoadjuvant chemotherapy in PhaseⅠ、Ⅱcases.The cases of xelox neoadjuvant chemotherapy is more than sox neoadjuvant chemotherapy in PhaseⅢ、Ⅳcases. (2) The rate of Her-2 protein expression is therefore 52%. The positive rate of Her-2 protein expression is higher than the negative rate in well-differentiated adenocarcinoma. The negative rate of Her-2 protein expression is higher than the positive rate in the poorly-differentiated adenocarcinoma. The negative rate of Her-2 protein expression is higher than the positive rate in PhaseⅠcases. The positive rate of Her-2 protein expression is higher than the negative rate in Phase Ⅲ cases. The positive rate of Her-2 protein expression is higher than the negative rate when tumors are developed at the cardia of stomach. The negative rate of Her-2 protein expression is higher than the positive rate when the tumors are developed at the lesser curvature of the stomach. (3) The rate of Ki-67 protein expression is therefore 45%. The positive rate of Ki-67 protein expression is higher than the negative rate in poorly-differentiated adenocarcinoma The negative rate of Ki-67protein expression is higher than the positive rate in PhaseⅠcases. The positive rate of Ki-67 protein expression is higher than the negative rate in PhaseⅢ cases. The positive rate of Ki-67 protein expression is higher than the negative rate when the tumors are developed at the cardia of the stomach. Conclusions:(1).Sox neoadjuvant chemotherapy in the treatment of gastric cancer is significantly better than xelox in terms of short-term effect. (2). The high exp...
URL查看原文
Language中文
Document Type学位论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/222572
Collection学院待认领
Affiliation临床医学院
Recommended Citation
GB/T 7714
赵若羽. 胃癌两种新辅助化疗方案比较及Her-2、Ki-67表达相关性研究[D]. 兰州. 兰州大学,2015.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[赵若羽]'s Articles
Baidu academic
Similar articles in Baidu academic
[赵若羽]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[赵若羽]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.